Amarin reported second-quarter 2026 results showing total net revenue of $42.2 million and a gross profit of $14.99 million, while GAAP net loss narrowed to $7.7 million. The company generated positive cash flow for the quarter, held $314.6 million in cash and short-term investments as of June 30, 2026, and reiterated an improved operating expense profile following a completed cost-savings initiative. Amarin highlighted rising in-market demand across its global partner network and continued U.S. market share leadership for VASCEPA.

Financial Highlights

  • Total net revenue: $42.2 million for Q2 2026 (down from $72.7 million in Q2 2025).
  • Product revenue, net: $39.1 million for Q2 2026; licensing & royalties: $3.1 million.
  • Gross profit: $14.99 million for Q2 2026 (gross margin shown in statements).
  • Operating loss: $(12.0) million for Q2 2026; Net loss: $(7.7) million for Q2 2026.
  • Cash position: $314.6 million as of June 30, 2026; Company expects cash to grow ~10% by Dec 31, 2026 vs Dec 31, 2025.

Business Highlights

  • International partnership with Recordati (entered June 2025) driving early commercial momentum; in-market demand across global partner network rose 59% year over year in Q2 2026.
  • In-market demand in Europe for VAZKEPA increased 69% in Q2 2026 vs Q2 2025; VAZKEPA commercialized in 11 European countries as of June 30, 2026.
  • China in-market volume grew 90% year to date versus the prior year period; VASCEPA/VAZKEPA commercially available in 22 countries globally as of June 30, 2026.
  • U.S. branded presence maintained: Amarin’s share of the U.S. IPE market increased to 48% in Q2 2026 (from 43% in Q2 2025) and branded VASCEPA prescriptions rose 14% year over year.
  • Completed a global restructuring and $70 million annual cost savings initiative, resulting in materially lower operating expense baseline and reduced SG&A run-rate.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.